Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Business Wire
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.“For over 16 years, Kelvin has been dedicated to financing and building life science companies around the world,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “His clinical knowledge and partnering expertise are a valuable complement to our Board of Directors as we advance our lead product candidates towards commercialization.”Dr. Neu is a Partner at Baker Bros. Advisors LP, a long term life-sciences investment firm. Kelvin earned his M.D. from the Harvard Medical School-MIT Health
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump's Tariff Rollout [Yahoo! Finance]Yahoo! Finance
- Zymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingGlobeNewswire
- Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "neutral" rating on the stock.MarketBeat
- Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates [Yahoo! Finance]Yahoo! Finance
ZYME
Earnings
- 3/5/25 - Beat
ZYME
Sec Filings
- 4/8/25 - Form SCHEDULE
- 4/7/25 - Form 4
- 4/2/25 - Form 4
- ZYME's page on the SEC website